Profile data is unavailable for this security.
About the company
Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
- Revenue in USD (TTM)56.66m
- Net income in USD-17.31m
- Incorporated2003
- Employees174.00
- LocationExagen Inc1261 Liberty WayVISTA 92081United StatesUSA
- Phone+1 (760) 560-1501
- Fax+1 (302) 655-5049
- Websitehttps://exagen.com/
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 30 Jun 2024 | 1.51m | 8.70% |
| TD Securities (USA) LLCas of 30 Jun 2024 | 891.37k | 5.13% |
| Wasatch Advisors LPas of 30 Jun 2024 | 762.26k | 4.38% |
| Silvercrest Asset Management Group LLCas of 30 Jun 2024 | 544.88k | 3.13% |
| Perkins Capital Management, Inc.as of 30 Jun 2024 | 493.32k | 2.84% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 486.80k | 2.80% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 482.42k | 2.78% |
| Stonepine Capital Management LLCas of 30 Jun 2024 | 358.70k | 2.06% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 94.23k | 0.54% |
| Geode Capital Management LLCas of 30 Jun 2024 | 87.62k | 0.50% |
